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ABSTRACT
Introduction: The aim of this study was to
evaluate quality of life after circumferential
pulmonary vein isolation (CPVI) compared
with antiarrhythmic drug therapy (ADT) in
treating atrial fibrillation (AF). CPVI is now a
common therapy in AF, but few studies have
focused on the effect of CPVI on quality of life.
Methods: A total of 123 AF patients were
followed prospectively. Quality of life was
evaluated comparing CPVI with ADT as a
second-line treatment for patients with AF.
The Medical Outcomes Study Short Form (SF)-
36 health surveys were conducted to establish a
baseline score before initiation and again at
6 months after the intervention.
Results: Mean follow-up duration was 12.7 ±
4.3 months. Of 123 patients enrolled, 66 were
randomized to receive CPVI and 57 to ADT alone.
At the 6-month follow-up, 13 (22.8%) patients in
the ADT group and 41 (62.1%) patients in the CPVI
grouphadnorecurrenceofAF.TheSF-36scaleswere
significantly higher in the CPVI than in the ADT
group, as were the physical component summary
scores (269.3 ± 58.6 vs. 234.9 ± 66.9) and mental
component summary scores (273.6 ± 69.4 vs.
234.1 ± 44.7). Quality of life was significantly
higher in the CPVI group (except for body pain).
Conclusion: In patients with AF, CPVI has
superiority over ADT with regards to the
maintenance of sinus rhythm and improvements
in quality of life.
Keywords: Circumferential pulmonary vein
isolation; Antiarrhythmic drug therapy; Atrial
fibrillation; Quality of life
INTRODUCTION
Atrial fibrillation (AF) is the most common
sustained cardiac arrhythmia. The prevalence
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has been increasing with the aging population
and the growing number of individuals who
survive with chronic cardiovascular diseases. AF
increases the risk of stroke and other embolic
events, and has been associated with
diminished functional status and heart failure
symptoms of diastolic dysfunction with the
development of dilated cardiomyopathy. It
considerably impairs the patients’ quality of
life (QoL). The technique of circumferential
pulmonary vein isolation (CPVI) has undergone
rapid evolution and has emerged as an
important strategy in the treatment of patients
with AF, although its effect on QoL has not
been fully characterized. The aim of the present
study was to evaluate effect on QoL score in
patients with AF after treatment with CPVI




The study included 123 patients with AF,
randomized to CPVI (n = 66) or ADT alone
(n = 57). All patients were followed-up for
6 months after the intervention.
QoL Assessment
QoL was assessed using the Medical Outcomes
Study Short Form-36 (SF-36) health survey
questionnaire [1]. The SF-36 assesses eight
specific QoL domains. It contains items to
assess physical health (general health percep-
tion, physical functioning, role limitations due
to physical problems, and bodily pain) and
mental health (social functioning, role
limitations due to emotional problems, mental
health, and vitality). The total score from the
eight scales can range from 0 to 100, with
higher scores representing better functioning
and QoL than lower scores.
CPVI
The right internal jugular vein or subclavian
vein was punctured while patients were under
local anesthesia (lidocaine). An electrode
catheter was introduced into the coronary
sinus to record left atrial electrical activity and
pacing. The intra-atrial septum was punctured
under X-ray guidance projected into a SWARTZ
L1 and R0 expansion scabbard along the sheath
pipe into the ablation catheter infused with a
cold saline catheter (St. Jude, USA) and LASSO
catheter (St. Jude, USA). Under X-ray guidance
and the EnSite3000 noncontact mapping
system, three-dimensional (3D) electro-
anatomic maps were constructed. The left and
right pulmonary veins were encircled, with
additional lines in the posterior left atrium or
roof and along the mitral isthmus for those who
had atrial flutter. Contiguous applications of
radiofrequency energy were delivered at a target
temperature of 50–60C and a maximal power
output of 40–50 W. The endpoint of ablation
was an 80% reduction in the amplitude of the
electrogram or a total of 40 s of energy
application. Additional ablation was performed
in the outer pulmonary veins, where the local
electrogram amplitude exceeded 0.2 mV. If AF
was still present at the end of circumferential
pulmonary vein ablation, either amiodarone or
transthoracic cardioversion was used to restore
sinus rhythm.
Follow-Up and Study Objectives
All patients were systematically followed up for
6 months after the intervention, with the
following parametric data obtained: 12-lead
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electrocardiography (ECG), echocardiography,
and 24-h Holter recording at baseline and 1, 3,
and 6 months. Additional 12-lead ECG or a
Holter measurement was encouraged when
patients experienced palpitations. QoL was
assessed using the SF-36 survey at baseline and
again at 6 months after the intervention.
Episodes were qualified as AF, if they lasted at
least 3 min and were documented by ECG/
Holter or reported by the patient as AF, even
in the absence of ECG confirmation.
Statistical Analysis
Analysis was carried out using SAS 16.0 statistical
software package. Continuous variables were
summarized by mean ± standard deviation or
the median and interquartile range (25th and
75th percentiles), and were compared using
t-tests or Wilcoxon rank sum test. Categorical
variables were represented by frequencies and
percentages, and were compared using v2 tests.




Clinical characteristics of 123 enrolled patients
are shown in Table 1. Sixty-six patients
underwent CPVI (45 males and 21 females
with the mean age of 61.5 ± 10.1 years). Fifty-
seven patients received ADT (35 males and 22
females with the mean age of 60.9 ±
13.7 years). The baseline characteristics were
comparable, with no significant differences
between two groups (e.g., age, gender,
paroxysmal AF or persistent AF, coronary
artery disease, hypertension, and valvular
heart disease; Tables 1, 2).
QoL at Baseline and at Follow-up
A total of 123 patients were prospectively
followed up for 6 months. At the 6-month
follow-up 13 (22.8%) patients in the ADT
group and 41 (62.1%) patients in the CPVI
group had no recurrence of AF. At baseline,
there were no significant differences in QoL
between the ADT and CPVI groups. Table 3
shows the changes in QoL from baseline to the
6-month follow-up assessment for the SF-36
scales pertaining to physical and mental health
in the CPVI group. For all scales the observation
was statistically significant different in the CPVI
group at baseline vs. 6 months (Table 3), For
seven of eight scales (except for body pain), the
observation was statistically significant at
baseline vs. 6 months in the CPVI group. The
6-month physical component summary (PCS)
and mental component summary (MCS) scores
Table 1 Baseline patient characteristics between circumferential pulmonary vein isolation (CPVI) and antiarrhythmic drug
therapy (ADT) group
Group Age (years) Total AF duration (years) Echocardiography Mean rate
LA (mm) LV (mm) EF
CPVI (n = 66) 61.5 ± 10.1 6.2 ± 5.6 39.2 ± 5.6 46.4 ± 4.9 58.5 ± 7.4 75.9 ± 19.3
ADT (n = 57) 60.9 ± 13.7 4.6 ± 6.2 39.1 ± 5.9 47.5 ± 6.4 58.1 ± 6.2 74.1 ± 20.1
t-value 0.27 1.51 0.12 1.04 0.36 0.51
P-value 0.79 0.14 0.91 0.91 0.30 0.61
AF atrial ﬁbrillation, EF ejection fraction, LA left arterial, LV left ventricular
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were increased significantly in the CPVI group
to 269.3 ± 58.6 and 273.6 ± 69.4, respectively
(within-group P\0.001 for both; Table 3). In
the ADT group, the PCS and MCS scores also
increased at 6 months to 234.9 ± 66.9 and
234.1 ± 44.7, respectively (within-group P\
0.05 for both; Table 3). However, at 6 months,
SF-36 scales were significantly higher in the
CPVI group than in the ADT group, as were the
PCS scores (269.3 ± 58.6 vs. 234.9 ± 66.9;
P\0.05) and MCS scores (273.6 ± 69.4 vs.
234.1 ± 44.7; P\0.001; Table 4).
Patients in the CPVI group were further
evaluated based on whether they had AF
recurrence. Among patients who had no AF
recurrence, the difference in all eight SF-36 scale






















CPVI 45 (68.1) 27 (40.9) 8 (12.1) 5 (7.6) 60 (90.9) 6 (9.1) 21 (37.5) 3 (4.5) 3 (4.5)
ADT 35 (61.4) 20 (35.1) 13 (22.8) 6 (10.5) 50 (87.7) 7 (12.3) 28 (49.1) 4 (7.0) 2 (3.5)
v2-value 0.62 0.44 0.47 0.33 0.33 4.84
P-value 0.43 0.51 0.12 0.57 0.57 0.39
AF atrial ﬁbrilation, CHD coronary heart disease, HC hypertensive cardiopathy, VHD valvular heart disease
Table 3 The mean changes from baseline to 6-months for the SF-36 scales









PF 67.1 ± 17.9 76.0 ± 17.5 0.005 62.1 ± 26.3 65.1 ± 20.4 0.494
RP 46.9 ± 17.6 58.0 ± 22.9 0.002 42.5 ± 20.6 48.9 ± 26.9 0.174
BP 58.6 ± 24.0 69.3 ± 21.2 0.007 60.6 ± 20.3 66.8 ± 22.2 0.120
GH 48.2 ± 20.7 66.0 ± 19.9 \0.001 42.9 ± 25.5 52.2 ± 26.8 0.023
VT 60.9 ± 16.5 70.8 ± 20.3 0.003 57.4 ± 17.5 62.8 ± 13.2 0.062
SF 56.4 ± 21.1 70.1 ± 24.3 0.001 53.3 ± 17.3 60.5 ± 17.7 0.030
MH 60.8 ± 15.9 72.4 ± 16.4 \0.001 60.1 ± 11.2 62.3 ± 12.2 0.324
RE 50.0 ± 25.0 60.4 ± 26.1 0.021 42.7 ± 25.8 48.4 ± 27.4 0.255
PCS 220.8 ± 54.6 269.3 ± 58.6 \0.001 208.2 ± 64.9 234.9 ± 66.9 0.033
MCS 228.1 ± 54.3 273.6 ± 69.4 \0.001 213.5 ± 44.5 234.1 ± 44.7 0.015
ADT antiarrhythmic drug therapy, BP bodily pain, CPVI circumferential pulmonary vein isolation, GH general health
perception, MCS mental component summary, MH mental health, PCS physical component summary, PF physical
functioning, RE role limitations due to emotional problems, RP role limitations due to physical problems, VT vitality, SF
social functioning
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measurements was statistically significant
between the baseline and 6-month evaluations.
Whereas the difference in all eight SF-36 scale
measurements in patients with AF recurrence
was statistically insignificant, except for the role
limitations due to emotional problems.
DISCUSSION
AF is the most common chronic arrhythmia
associated with an adverse prognosis. It is an
independent risk factor for stroke, resulting in
an approximate three- to fivefold excess risk [2].
Furthermore, the risks attributable to most
stroke risk factors decline with advancing age
[2]. AF causes disabling symptoms such as
fatigue, dyspnea, and palpitations. As a result,
the patient’s QoL may be drastically reduced.
The study showed that AF was associated with a
1.5–1.9-fold increased risk of mortality and was
an independent predictor of mortality with
stroke [3]. At present, more attention is
focused on the research and treatment of AF
in order to improve the QoL of patients with
this disorder.
This study demonstrated that the SF-36
scales were significantly higher in patients
treated with CPVI compared to ADT for all
physical and mental health assessments except
for body pain. The results of the present study
indicate that compared with ADT, CPVI is more
likely to maintain sinus rhythm, reduce
dyspnea, palpitations, and stroke, and improve
the QoL of AF patients.
In two previous trials, radiofrequency
catheter ablation appeared superior to ADT
treatment in improving symptoms and QoL [3,
4], which concurs with the present study. The
results of a multicenter trial comparing
catheter ablation with ADT in patients with
symptomatic, paroxysmal AF refractory to one
or more drugs showed the clear superiority of
ablation on rhythm-related endpoints [5]. A
different multicenter clinical trial that






PF 76.0 ± 17.5 65.1 ± 20.4 0.002
RP 58.0 ± 22.9 48.9 ± 26.9 0.041
BP 69.3 ± 21.2 66.8 ± 22.2 0.528
GH 66.0 ± 19.9 52.2 ± 26.8 0.007
VT 70.8 ± 20.3 62.8 ± 13.2 0.010
SF 70.1 ± 24.3 60.5 ± 17.7 0.013
MH 72.4 ± 16.4 62.3 ± 12.2 \0.001
RE 60.4 ± 26.1 48.4 ± 27.4 0.015
PCS 269.3 ± 58.6 234.9 ± 66.9 0.003
MCS 273.6 ± 69.4 234.1 ± 44.7 \0.001
ADT antiarrhythmic drug therapy, BP bodily pain, CPVI circumferential pulmonary vein isolation, GH general health
perception, MCS mental component summary, MH mental health, PCS physical component summary, PF physical
functioning, RE role limitations due to emotional problems, RP role limitations due to physical problems, VT vitality, SF
social functioning
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evaluated symptoms and QoL comparing
catheter ablation with ADT as a second-line
treatment for patients with paroxysmal AF
concluded that ablation is superior to ADT at
improving symptoms and QoL [6].
The results from a recent study by Wokhlu
et al. [7] which enrolled 323 patients, showed
that 72% of patients achieved AF elimination
off ADT, 15% achieved AF control on ADT, and
13% had recurrent AF after 2 years of follow-up.
The PCS and MCS scores also showed a
noteworthy increase. The results of several
trials have shown that radiofrequency catheter
ablation is superior to ADT at maintaining sinus
rhythm, primarily as a second-line treatment
[8–11]. In the present study, after a mean
follow-up of 12.7 ± 4.3 months, 22.8% and
62.1% of the ADT group and CPVI group,
respectively, had no recurrence of AF. At
6 month, the PCS and MCS scores increased
considerably in both the CPVI group and the
ADT group. CPVI has a higher success rate and,
thus, results in an elevated QoL.
The results of the Atrial Fibrillation Follow-up
Investigation of Rhythm Management (AFFIRM)
study [12] showed that there were no differences
in survival or event rates in patients with AF
randomized either to ventricular rate control or
heart rhythm control. The QoL scores were
comparable between the rate control and
rhythm control interventions. In addition, QoL
was similar with sinus rhythm versus AF control.
Attempts to improve QoL by restoring sinus
rhythm were usually unsuccessful [12]. A
multicenter trial demonstrated that a routine
strategy of heart rhythm control such as
metoprolol or amiodarone does not reduce the
rate of death from cardiovascular causes, as
compared with a rate-control strategy [13].
In previous studies, the restoration and
maintenance of sinus rhythm were often
attempted with electrical cardioversion and
ADT. However, the favorable outcome acquired
by restoring the sinus rhythm was counteracted
by the increased risk of adverse effects from ADT.
In this study, patients in the CPVI group were
sorted into two groups based on AF recurrence: no
AF recurrence group and AF recurrence group. In
the noAFrecurrencegroup, there wasa significant
difference in all eight SF-36 scales, but there was
no statistically significant difference in the
recurrence AF group, except for role limitations
due to emotional problems. AF impaired QoL and
was related to increased frequency anddurationof
disease and disease indexes. The present results
show that restoration and maintenance of sinus
rhythm can improve the QoL.
The effect of ADT on the QoL of patients
with AF is still controversial [8, 12, 13]. A study
by Dorian et al. [14] has suggested that QoL
improvements were not significantly different
among the groups randomized to amiodarone,
sotalol, or propafenone, and this was especially
true for patients in whom treatment prevented
AF recurrence. The study found that general
health perception, social functioning, and
physical and mental health summary measures
of the SF-36 scales improved significantly from
baseline to 6 months. Thus, indicating the lack
of superiority of ADT over ablation in patients
with AF with regard to maintenance of sinus
rhythm and improvement in QoL.
In summary, CPVI is superior to ADT in
patients with AF regarding the maintenance of
sinus rhythm and improvement in QoL,
especially in patients in whom CPVI was
successful.
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